Qiagen N.V. $QGEN Shares Bought by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC increased its stake in Qiagen N.V. by 52.3%, now owning approximately 245,657 shares valued at nearly $9.85 million.
• Several hedge funds, including Price T. Rowe Associates and Deutsche Bank AG, have made significant increases in their stakes, indicating strong institutional interest in Qiagen.
• Qiagen's earnings report showed a 7.7% year-over-year revenue increase with an EPS of $0.60, aligning with analyst expectations, and it has set its Q3 2025 EPS guidance at 0.580.

Voya Investment Management LLC increased its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 52.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 245,657 shares of the company's stock after buying an additional 84,332 shares during the quarter. Voya Investment Management LLC owned about 0.11% of Qiagen worth $9,845,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. SVB Wealth LLC purchased a new stake in shares of Qiagen during the 1st quarter valued at approximately $31,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Qiagen during the 1st quarter valued at approximately $94,000. GAMMA Investing LLC increased its holdings in Qiagen by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Qiagen in the 1st quarter valued at approximately $150,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Qiagen in the 4th quarter valued at approximately $202,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Stock Up 0.4%

Shares of Qiagen stock traded up $0.20 during trading on Friday, hitting $45.94. 571,566 shares of the stock were exchanged, compared to its average volume of 1,374,492. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of 27.14, a price-to-earnings-growth ratio of 2.40 and a beta of 0.64. The firm's 50-day moving average price is $48.27 and its 200 day moving average price is $44.78. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same period in the previous year, the company earned $0.55 EPS. The company's revenue for the quarter was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on QGEN shares. Barclays started coverage on shares of Qiagen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. Bank of America lifted their target price on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Wall Street Zen downgraded shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Cowen restated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, UBS Group boosted their price target on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.